US EditionPublished • loading... • Updated
Aurobindo launches Citalopram Capsules
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Aurobindo launches Citalopram Capsules
EAST WINDSOR, N.J. – Aurobindo Pharma USA announces the launch of Citalopram Capsules. Citalopram Capsules are indicated for the treatment of Major Depressive Disorder (MDD) in adults.According to IQVIA, U.S. annual sales for Citalopram Capsules were approximately $5.1 million for the 12 months ending Jan 2026. Product Details:• Strength: 30 mg Prescribing InformationFor more details on Aurobindo’s Citalopram Capsules, visit Citalopram Capsules…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
